Zhang Ying, Wang Wei, Xie Yubing, Yu Weiting, Teng Huaining, Liu Xiudong, Zhang Xulang, Guo Xin, Fei Jian, Ma Xiaojun
Laboratory of Biomedical Material Engineering, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, People's Republic of China.
Hum Gene Ther. 2007 May;18(5):474-81. doi: 10.1089/hum.2006.166.
Microencapsulation of recombinant cells is a novel alternative approach to tumor gene therapy. Therapeutic protein delivery can be sustained for systemic treatment of tumors because the recombinant cells are enclosed in microcapsules and the semipermeable membrane of the microcapsules protects the cells from host immune rejection and reduces the need for frequent injection. In this study, we describe a method to systemically inhibit tumor growth by in vivo culture of antiangiogenic endostatin-secreting Chinese hamster ovary (CHO) cells in microcapsules as small as 200 microm in diameter. Peritoneal administration of encapsulated endostatin-CHO cells inhibited melanoma growth to 66.4% and enhanced the survival of treated mice to 80% by 27 days posttreatment. Continuous systemic release of endostatin from microcapsules offers an effective therapeutic strategy to eradicate solid tumors.
重组细胞的微囊化是肿瘤基因治疗的一种新型替代方法。由于重组细胞被包裹在微囊中，且微囊的半透膜可保护细胞免受宿主免疫排斥并减少频繁注射的需求，因此治疗性蛋白质的递送可持续用于肿瘤的全身治疗。在本研究中，我们描述了一种通过在直径小至200微米的微囊中体内培养分泌抗血管生成内皮抑素的中国仓鼠卵巢（CHO）细胞来全身抑制肿瘤生长的方法。腹腔注射包囊化的内皮抑素-CHO细胞可将黑色素瘤的生长抑制至66.4%，并使治疗小鼠在治疗后27天的存活率提高至80%。微囊中内皮抑素的持续全身释放为根除实体瘤提供了一种有效的治疗策略。
